Clinical roundtable monograph. The oncologist's role in management of XXXX .

@entity1 @entity5 @entity1151 @entity1031 @entity1211 @entity204
@entity1031 is the second leading cause of @entity204 in @entity5 @entity1 . @entity1 with @entity1211 ( @entity1211 ) and @entity5 have a significantly higher probability of @entity204 . @entity1151 can lead to a fatal outcome, and this condition often goes undiagnosed in @entity5 @entity1 despite the presence of symptoms. Risk of @entity1211 is increased by a number of clinical factors, which can be @entity1 -derived, @entity5 -related, and treatment-related. Increasingly, clinicians are seeking predictable biomarkers to identify those @entity1 at the greatest risk. To that end, a newly developed and validated predictive risk model may help identify @entity1 who could benefit from prophylaxis. In addition, serum levels of coagulation cascade factors may predict the survival rate of @entity5 @entity1 ; elevated D-dimer levels are associated with decreased survival time. Anticoagulants, particularly low-molecular-weight heparin, can be useful in preventing the recurrence of clots in @entity5 @entity1 with @entity1211 . Current and future investigations are aimed at determining if prophylaxis with anticoagulants can improve @entity1 survival. Future management strategies may involve the use of low-molecular-weight heparin or other novel anticoagulants as part of palliative care for high-risk @entity1 . Although treatment with low-molecular-weight heparin can significantly reduce the risks of clots, the impact on @entity5 survival is unclear.
